In mouse melanoma models with BRAFV600E, the MEK inhibitor trametinib demonstrated enhanced antitumor activity when used alongside immunotherapy and the BRAF inhibitor dabrafenib[141]. This evidence concerns the gene MAP2K7 and melanoma.